AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02709434 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard care
Description: Usual IBD management
Study NCT02709434 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Usual IBD management
Study NCT02306187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edirol
Description: Edirol 0.5 or 0.75ug once every day oral treatment for at least 1 year after initial visit.
Study NCT02156635 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Placebo
Study NCT02631499 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: TACE is performed 4-6 weeks after hepatectomy. Epirubicin and lipiodol are used in TACE.
Study NCT01839188 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PR5I
Description: Hexavalent PR5I vaccine (DTaP-HB-IPV-Hib = Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed \[DTaP\], Hepatitis B \[HB; Recombinant DNA\], Inactivated Poliovirus \[IPV\], and Haemophilus influenzae type b \[Hib\] conjugate vaccine \[adsorbed\]) at 0.5 mL for IM injection (left upper thigh) at 2 and 6 months of age.
Study NCT01839188 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pediacel®
Description: Pentavalent Pediacel® vaccine (DTaP-IPV-Hib = Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed \[DTaP\], Inactivated Poliovirus \[IPV\], and Haemophilus influenzae type b \[Hib\] conjugate vaccine \[adsorbed\]) at 0.5 mL for IM injection (left upper thigh) at 4 months of age.
Study NCT02631499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Epirubicin is a chemotherapy drug used in TACE
Study NCT02631499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lipiodol
Description: lipiodol is a kind of embolization material used in TACE
Study NCT01839188 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NeisVac-C®
Description: Meningococcal group C (MCC) polysaccharide conjugate vaccine (adsorbed) at 0.5 mL for IM injection (right upper thigh) at 2 and 4 months of age.
Study NCT01839188 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RotaTeq®
Description: Human-bovine rotavirus reassortants (live) vaccine 2 mL oral administration at 2, 4 and 6 months of age. RotaTeq® administered prior to any other vaccine administration to avoid having the infant participants spit up the RotaTeq® when crying.
Study NCT01839188 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevenar 13®
Description: Pneumococcal polysaccharide conjugate vaccine \[PCV; 13-valent, adsorbed\]) at 0.5 mL for IM injection (right upper thigh) at 2 and 4 months of age.
Study NCT03314363 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: blood gas analysis under NaCl predilution
Description: repeat blood gas analysis of blood on different sample points and dialysis fluid
Study NCT03355287 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Traditionally Threshed Teff (TTT)
Description: The intervention will take place for 7 months in Debre Zeit where the the arm will be fed injera based on teff that are threshed traditionally
Study NCT03355287 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lab Threshed Teff (LTT)
Description: The intervention will take place for 7 months in Debre Zeit where this arm will be fed injera from teff that is threshed using a modern thresher.
Study NCT03355287 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fortified Lab Threshed Teff (FTT)
Description: The intervention will take place for 7 months in Debre Zeit where this arm will be fed injera from teff that is threshed using a modern thresher. In addition, they will receive Ferrous sulfate drops
Study NCT03167580 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: restricted PEEP
Description: Patients are randomized and ventilated with restricted PEEP (the lowest possible PEEP level, 0 - 5 cm H2O)
Study NCT03167580 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: liberal PEEP
Description: Patients are randomized and ventilated with liberal PEEP (the median PEEP level used in the Netherlands, 8 cm H2O)
Study NCT03870711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine spray
Description: 10% lidocaine spray 4 puffs
Study NCT03870711 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile water 4 puffs
Study NCT01524445 — intervention group
Intervention type: OTHER
Intervention: bortezomib retreatment due to relapse
Description: Patients who received bortezomib-containing chemotherapy as first-line treatment for MM, experienced partial response or better, and were re-treated (second-line) with bortezomib (for at least 3 cycles) due to a relapse of the disease after a treatment free interruption of at least 6 months
Study NCT01924546 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water
Description: 1.5 L bottle of water provided in the morning of the school day, with refills provided during the course of the day.
Study NCT03606252 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood sampling
Description: 6 blood sample, 3 at J0 and 3 at J7 ( 2 tubes EDTA of 7mL, 1 tube Blood RNA of 3 mL)
Study NCT03850067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide
Study NCT03850067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab
Study NCT03606252 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: urine sampling
Description: 2 urine sample (1 at J0 and 1 at J7)
Study NCT03885726 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Precision Flow Plus
Description: High velocity nasal insufflation
Study NCT03885726 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Conventional therapy per institution
Study NCT02034357 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Neurocognitive function
Description: Each eligible participant will complete a neuro-cognitive assessment as measured by CVLT at the beginning of the study. Neurocognitive evaluations will be repeated at 4-month and 1-year follow-up.
Study NCT02034357 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Sleep evaluations
Description: Each eligible participant will complete sleep questionnaires and undergo a baseline sleep study at the beginning of the study. The sleep questionnaires will be repeated at 4-month and 1-year follow-up.
Study NCT04078152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: IV infusion q4w with 1500mg durvalumab until progressive disease
Study NCT03223090 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tool-use
Description: Motor training with a tool during max 5 weeks (3 days per week, around 30 minutes per day)
Study NCT03223090 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Hand
Description: Motor training with the right hand during max 5 weeks (3 days per week, around 30 minutes per day)
Study NCT03757481 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: no intervention
Description: SF-36 questionnaire , PembQoL, Villalta score ,PembQoL
Study NCT02519244 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ekso® (Wearable lower limb exoskeleton)
Description: The wearable lower limb exoskeleton is a powered, robotic lower limb exoskeleton with actuated hips and knees. A control algorithm has been implemented in this device, which allows for provision of assistance to lower limb segments during movement, dependent on user needs.
Study NCT04757779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anlotinib hydrochloride combined with irinotecan or docetaxel
Description: From the start of the study, the subjects are orally administered with anlotinib 12mg on empty stomach.Subjects need to take anlotinib 2 weeks continuously and stop for 1 week(every 3 weeks is a cycle),the dose of anlotinib can be adjusted as 12mg,10mg or 8mg according to adverse effects.On Day1 and Day8, subjects are required to inject irinotecan (65mg/m2)or docetaxel (60mg/m2) of a cycle,until disease progression or intolerable toxicity, for 4 cycles at most.
Study NCT04478682 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breastfeeding Support Provided to Mothers Through WhatsApp Messaging Application
Description: Breastfeeding support provided to mothers through WhatsApp messaging application will be maintained for the first 6 months after birth. In the first 1 month, standard information sharing will be made through whatsApp. Also, for the first 6 months, solutions generating shares will be made according to the problems and questions of the mother regarding breastfeeding.
Study NCT01883440 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucose oxidase + glucose
Description: Isotone saline + 200U/ml of glucose oxidase + 5% of glucose in a bag on valve nasal spray device
Study NCT01883440 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline+glucose
Description: Placebo arm
Study NCT01064453 — intervention group
Intervention type: DRUG
Intervention: E2/DRSP (Angeliq, BAY86-4891)
Description: Take one tablet daily, continuously
Study NCT00035425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: linezolid
Description: 600mg every 12 hours
Study NCT00035425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vancomycin
Description: 1gm every 12 hours. The dose of vancomycin intravenously may be adjusted for renal function, but the patient must be able to receive a 300 mL volume of intravenous fluid at the assigned dosing times of every 12 hours.
Study NCT01661400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronomic Cyclophosphamide
Study NCT03189524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Zanubrutinib is a white to off-white solid that is slightly hygroscopic. The drug product was formulated as 20-mg (blue, size 3) and 80-mg (white, size 0) hard gelatin, opaque oral capsules. Zanubrutinib is classified as a Biopharmaceutics Classification System Class II compound.
Study NCT03314363 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: double ultrafiltration
Description: double the ultrafiltration fluid by augmenting post dilution fluid and keeping ultrafiltration at the same rate.
Study NCT03314363 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: blood gas analysis under citrate predilution and double ultrafiltration rate
Description: repeat blood gas analysis of blood on different sample points and dialysis fluid
Study NCT03314363 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: pause and restart nutritional therapy
Description: pause parenteral and enteral nutrition before indirect calorimetry is performed. and restart after first blood analysis for vitamine status
Study NCT03314363 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: evolution of vitamin and trace elements
Description: blood analysis for vitamin and trace elements. Perform this blood analysis after restart of CRRT but before restart of nutritional therapy, 30 minutes after restart of nutritional therapy and 24h after restart of nutritional therapy.
Study NCT01525576 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Booster
Description: 3 week booster program + 2 additional weeks two months later for follow-up.
Study NCT02183246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Porfiromycin
Study NCT02183246 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02183246 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Radiotherapy
Study NCT02183246 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Study NCT04455971 — intervention group
Intervention type: BEHAVIORAL
Intervention: Orgasmic Meditation
Description: Orgasmic Meditation (OM) is a form of meditation that increases bodily awareness during structured, partnered female genital stimulation over a 15-minute period.
Study NCT04619550 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: High tibial osteotomy
Description: Realignment surgery
Study NCT01075061 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: healthy volunteers
Description: morphological and functional brain MRI; transcranial magnetic stimulation
Study NCT01075061 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Kallmann
Description: morphological and functional brain MRI; transcranial magnetic stimulation
Study NCT01075061 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Congenital Mirror Movement
Description: morphological and functional brain MRI; transcranial magnetic stimulation
Study NCT04540718 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 50 minutes of exercise, consisting of 20 minutes of resistance followed by 30 minutes of aerobic, three times a week for eight weeks.
Study NCT04540718 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: 50 minutes of exercise, consisting of 20 minutes of resistance followed by 30 minutes of aerobic, three times a week for eight weeks.
Study NCT04540718 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sauna
Description: 15 minutes of sauna exposure immediately after exercise intervention, three times a week for eight weeks.
Study NCT01560884 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Renazorb 1500 mg/day
Description: Six subjects will be randomly assigned to receive SPI-014 1500 mg/day dose and 2 subjects to receive placebo
Study NCT01560884 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Renazorb 3000 mg/day
Description: Six subjects will be randomly assigned to receive SPI-014 3000 mg/day dose and 2 subjects to receive placebo
Study NCT01560884 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Renazorb 4500 mg/day
Description: Six subjects will be randomly assigned to receive SPI-014 4500 mg/day dose and 2 subjects to receive placebo
Study NCT01560884 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Renazorb 6000 mg/day
Description: Six subjects will be randomly assigned to receive SPI-014 6000 mg/day dose and 2 subjects to receive placebo
Study NCT05247333 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Minor ailment service
Description: The service had several components: agreed standard operational procedures between community pharmacists and primary care physicians for 31 minor ailments, IT based consultation protocol and training before and during the study for the pharmacists. Practice change facilitators were used to confirm the fidelity of the intervention.
Study NCT01661400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Study NCT05565261 — intervention group
Intervention type: DEVICE
Intervention: complete denture
Description: Bite force was measured with a bite force measuring device. Quality of life and patient satisfaction were evaluated with questionnaires.
Study NCT04421989 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotion Coaching
Description: Participants randomized to FBT + EC parent group condition will also receive FBT as part of their standard of care. In addition to FBT, they will receive 10 additional, weekly, parent group sessions (each session is 60 minutes, 6-8 group members), within a 3-month time frame to account for cancellations. The EC intervention is designed to reduce expressed emotion (e.g., critical comments) and increase parental warmth. The intervention includes emotional awareness and emotion regulation skills for parents, and emotion communication skills for parents to use with their teens undergoing FBT including active listening, emotion support, labeling emotions, and coping with emotions. The structure of EC parent group sessions will begin with review of homework as applicable, a didactic component to teach new skills, followed by role plays between parents in the group and interventionist, and live coaching and feedback from the interventionist.
Study NCT04421989 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Support Group
Description: Participants randomized to FBT + Support Group parent group condition will also receive FBT as part of their standard of care. In addition to FBT, they will receive 10 additional, weekly, parent group sessions (each session is 60 minutes, 6-8 group members), within a 3-month time frame to account for cancellations. The support group will have a facilitator introduce each topic weekly and parents will discuss. The facilitator's role is to ensure the group remains on topic and on time. Weekly discussion topics include: co-morbid medical diagnoses, understanding levels of care in treatment, taking time off from work, and medications.
Study NCT02885350 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spinal analgesia for labour pain
Description: Intrathecal dose of either fentanyl or sufentanil delivered by combined spinal-epidural technique
Study NCT02885350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epidural analgesia for labour pain
Description: Epidural dose of either fentanyl or sufentanil delivered through an epidural catheter.
Study NCT00392678 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salsalate
Description: Placebo and Salsalate 3.0 g/d; 3.5 g/d; 4.0 g/d orally, divided
Study NCT00392678 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to Salsalate
Study NCT00336232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin K
Description: phylloquinone (vitamin K1) 500 mcg daily in third month
Study NCT00640029 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthrodesis
Description: * posterior,~* anterior,~* circumference approach
Study NCT03288272 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Whole Brain Radiotherapy
Description: Radiotherapy of the whole brain
Study NCT03288272 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Supportive Care
Description: Best Supportive Care including nutrition, pain medication, steroids as needed
Study NCT00640029 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arthroplasty (PRODISC-C® , PRODISC-L®, Mobi-C®, Mobidisc®, PrestigeLP®, A-Mav®, O-Mav®, DISCOCERV®)
Description: * SYNTHES : PRODISC-C® , PRODISC-L®~* LDR : Mobi-C®, Mobidisc®~* MEDTRONIC : PrestigeLP®, A-Mav®, O-Mav®~* SCIENT'X : DISCOCERV®
Study NCT00086840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temsirolimus
Description: Given IV
Study NCT00086840 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00940342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF (Sargramostim)
Description: 250 mcg injection under the skin, three times a week for eight weeks.
Study NCT00940342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2 administered intravenously once weekly for four weeks
Study NCT01540188 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Intervention to Address Drug Use and HIV in Vietnam
Description: Intervention for IDUs: there are 4 sessions of the intervention with the following titles: My family, my health, my actions, my community.~Intervention for family members: there are 4 intervention sessions for family members covering the following topics: my family, my responsibility, my support and my community
Study NCT03866863 — intervention group
Intervention type: OTHER
Intervention: Intrauterine growth restriction (IUGR)
Description: Collection of number of patient's diagnosed with IUGR as defined in accordance with the consensus-based definition for early and late IUGR : birthweight \< 3rd centile using French AUDIPOG curves adjusted for term and sex or estimated fetal weight \< 10th centile combined with umbilical artery pulsatility index > 95th centile or breakage of growth.
Study NCT02028104 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow mononuclear cell transplantation
Description: bone marrow derived mononuclear cells are administered intrathecally in traumatic brain injury patients
Study NCT02500199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib
Description: Pyrotinib maleate, is provided as yellow, film-coated, immediate release tablets containing pyrotinib maleate at dosage strengths of 80 and 160 mg. Multiple tablets of pyrotinib will be administered daily to achieve targeted doses of pyrotinib: 320 mg, 400 mg, 480 mg, 560 mg and 640 mg. Tablets will be orally administered with water, once daily, 30 min after a meal.
Study NCT00488618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine (RGH-188)
Description: Cariprazine 3 mg - 12 mg oral administration, once per day.
Study NCT00488618 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dose-matched placebo oral administration, once per day.
Study NCT03887559 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group-based stabilization and skill training in addition to individual treatment
Description: Group-based stabilization and skill training, weekly 2-hour sessions during 20 weeks. Based on the manual Tilbake til Nåtid (Back to here and now) (Holbæk, 2014) developed by clinicians in the highly specialized national trauma clinic 'Modum Bad's Trauma Clinic'.
Study NCT03887559 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Treatment as usual: conventional individual treatment (outpatient). Not standardized.
Study NCT02256865 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketoconazole
Description: Ketoconazole is taken 4 times a day